Investor Relations
This section of the Co-Diagnostics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Co-Diagnosticsassumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQCODX
Beta | (0.52) |
---|---|
Shares Outstanding | 30.9M |
Average Volume (10 days) | 104.4K |
Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
Current Mean Recommendation | Buy |
---|
Strong Buy | 2 | |
---|---|---|
Buy | 0 | |
Hold | 2 | |
Underperform | 0 | |
Sell | 0 |
Recent Insider Transactions
Richard S. Serbin Director | 12,500 Acquire Jan 8, 2023 |
---|---|
James Nelson Director | 12,500 Acquire Jan 8, 2023 |
Eugene Durenard Director | 12,500 Acquire Jan 8, 2023 |
Dwight H Egan Director, Chief Executive Officer | (32,110) Dispose Nov 23, 2022 |
Brian L. Brown Chief Financial Officer | (18,187) Dispose Nov 23, 2022 |